REFERENCES
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229-63.
2. Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell 2023;186:1708-28.
3. Wang J, Li B, Luo M, et al. Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance. Signal Transduct Target Ther 2024;9:83.
4. Purrahman D, Mahmoudian-Sani MR, Saki N, Wojdasiewicz P, Kurkowska-Jastrzębska I, Poniatowski ŁA. Involvement of progranulin (PGRN) in the pathogenesis and prognosis of breast cancer. Cytokine 2022;151:155803.
5. He B, Zhao Z, Cai Q, et al. miRNA-based biomarkers, therapies, and resistance in Cancer. Int J Biol Sci 2020;16:2628-47.
7. Syed R, Davey MG, Richard V, Miller N, Kerin MJ. Biological implications of MicroRNAs as regulators and biomarkers of therapeutic toxicities in breast cancer. Int J Mol Sci 2023;24:12694.
8. Hill M, Tran N. miRNA interplay: mechanisms and consequences in cancer. Dis Model Mech 2021;14:dmm047662.
9. Vishnoi A, Rani S. miRNA biogenesis and regulation of diseases: an updated overview. Methods Mol Biol 2023;2595:1-12.
10. Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol 2019;234:5451-65.
12. Zeng Y, Du W, Huang Z, et al. Hsa_circ_0060467 promotes breast cancer liver metastasis by complexing with eIF4A3 and sponging miR-1205. Cell Death Discov 2023;9:153.
13. Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 2013;495:333-8.
14. Ashwal-Fluss R, Meyer M, Pamudurti NR, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell 2014;56:55-66.
15. Yarmishyn AA, Ishola AA, Chen CY, et al. Circular RNAs modulate cancer hallmark and molecular pathways to support cancer progression and metastasis. Cancers 2022;14:862.
16. Li Y, Wang Z, Yang J, et al. CircTRIM1 encodes TRIM1-269aa to promote chemoresistance and metastasis of TNBC via enhancing CaM-dependent MARCKS translocation and PI3K/AKT/mTOR activation. Mol Cancer 2024;23:102.
17. Song X, Wang X, Chen X, Yu Z, Zhou Y. SRSF1 inhibits ferroptosis and reduces cisplatin chemosensitivity of triple-negative breast cancer cells through the circSEPT9/GCH1 axis. J Proteomics 2024;292:105055.
18. Wang H, Wang X, Shen W, et al. CircRNA (circ)_0007823 contributes to triple-negative breast cancer progression and cisplatin resistance via the miR-182-5p/FOXO1 pathway. Biochem Genet 2024:1-13.
20. Matsuyama H, Suzuki HI. Systems and synthetic microRNA biology: from biogenesis to disease pathogenesis. Int J Mol Sci 2019;21:132.
21. Pietrykowska H, Sierocka I, Zielezinski A, et al. Biogenesis, conservation, and function of miRNA in liverworts. J Exp Bot 2022;73:4528-45.
22. Tafrihi M, Hasheminasab E. MiRNAs: Biology, biogenesis, their web-based tools, and databases. Microrna 2019;8:4-27.
23. Do DN, Dudemaine PL, Mathur M, Suravajhala P, Zhao X, Ibeagha-Awemu EM. miRNA regulatory functions in farm animal diseases, and biomarker potentials for effective therapies. Int J Mol Sci 2021;22:3080.
24. Kilikevicius A, Meister G, Corey DR. Reexamining assumptions about miRNA-guided gene silencing. Nucleic Acids Res 2022;50:617-34.
25. Pu M, Chen J, Tao Z, et al. Regulatory network of miRNA on its target: coordination between transcriptional and post-transcriptional regulation of gene expression. Cell Mol Life Sci 2019;76:441-51.
26. Yang L, Wilusz JE, Chen LL. Biogenesis and regulatory roles of circular RNAs. Annu Rev Cell Dev Biol 2022;38:263-89.
27. Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol 2020;21:475-90.
28. Chen LL. The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol 2016;17:205-11.
29. Huang X, Song C, Zhang J, Zhu L, Tang H. Circular RNAs in breast cancer diagnosis, treatment and prognosis. Oncol Res 2023;32:241-9.
30. Zhu Y, Huang G, Li S, et al. CircSMARCA5: a key circular RNA in various human diseases. Front Genet 2022;13:921306.
31. Wang Z, Yang L, Wu P, et al. The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin. Mol Cancer 2022;21:29.
32. Li Z, Ruan Y, Zhang H, Shen Y, Li T, Xiao B. Tumor-suppressive circular RNAs: mechanisms underlying their suppression of tumor occurrence and use as therapeutic targets. Cancer Sci 2019;110:3630-8.
33. Li X, Yang L, Chen LL. The biogenesis, functions, and challenges of circular RNAs. Mol Cell 2018;71:428-42.
34. Wu S, Lu J, Zhu H, et al. A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer. Cancer Lett 2024;581:216508.
35. Zhang M, Bai X, Zeng X, Liu J, Liu F, Zhang Z. circRNA-miRNA-mRNA in breast cancer. Clin Chim Acta 2021;523:120-30.
36. Huang A, Zheng H, Wu Z, Chen M, Huang Y. Circular RNA-protein interactions: functions, mechanisms, and identification. Theranostics 2020;10:3503-17.
37. Li M, Zou X, Xia T, et al. A five-miRNA panel in plasma was identified for breast cancer diagnosis. Cancer Med 2019;8:7006-17.
38. Wang YW, Xu Y, Wang YY, et al. Elevated circRNAs circ_0000745, circ_0001531 and circ_0001640 in human whole blood: potential novel diagnostic biomarkers for breast cancer. Exp Mol Pathol 2021;121:104661.
39. Kurozumi S, Seki N, Narusawa E, et al. Identification of microRNAs associated with histological grade in early-stage invasive breast cancer. Int J Mol Sci 2023;25:35.
40. Verma VK, Beevi SS, Nair RA, et al. MicroRNA signatures differentiate types, grades, and stages of breast invasive ductal carcinoma (IDC): miRNA-target interacting signaling pathways. Cell Commun Signal 2024;22:100.
41. Li X, Zou W, Wang Y, et al. Plasma-based microRNA signatures in early diagnosis of breast cancer. Mol Genet Genomic Med 2020;8:e1092.
42. Jiang W, Yu Y, Ou J, Li Y, Zhu N. Exosomal circRNA RHOT1 promotes breast cancer progression by targeting miR-204-5p/ PRMT5 axis. Cancer Cell Int 2023;23:260.
43. Turco C, Esposito G, Iaiza A, et al. MALAT1-dependent hsa_circ_0076611 regulates translation rate in triple-negative breast cancer. Commun Biol 2022;5:598.
44. Yang SJ, Wang DD, Zhong SL, et al. Tumor-derived exosomal circPSMA1 facilitates the tumorigenesis, metastasis, and migration in triple-negative breast cancer (TNBC) through miR-637/Akt1/β-catenin (cyclin D1) axis. Cell Death Dis 2021;12:420.
45. Wang B, Mao JH, Wang BY, et al. Exosomal miR-1910-3p promotes proliferation, metastasis, and autophagy of breast cancer cells by targeting MTMR3 and activating the NF-κB signaling pathway. Cancer Lett 2020;489:87-99.
46. Shiino S, Matsuzaki J, Shimomura A, et al. Serum miRNA-based prediction of axillary lymph node metastasis in breast cancer. Clin Cancer Res 2019;25:1817-27.
47. Wang H, Tan Z, Hu H, et al. microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1. BMC Cancer 2019;19:738.
48. Yuan X, Qian N, Ling S, et al. Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of tumor cells. Theranostics 2021;11:1429-45.
49. Alunni-Fabbroni M, Majunke L, Trapp EK, et al; SUCCESS Study Group. Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients. BMC Cancer 2018;18:141.
50. Bao S, Hu T, Liu J, et al. Genomic instability-derived plasma extracellular vesicle-microRNA signature as a minimally invasive predictor of risk and unfavorable prognosis in breast cancer. J Nanobiotechnology 2021;19:22.
51. Raghu A, Magendhra Rao AKD, Rajkumar T, Mani S. Prognostic implications of microRNA-155, -133a, -21 and -205 in breast cancer patients’ plasma. Microrna 2021;10:206-18.
52. Liu B, Pan J, Fu C. Correlation of microRNA-367 in the clinicopathologic features and prognosis of breast cancer patients. Medicine 2021;100:e26103.
53. Záveský L, Jandáková E, Weinberger V, et al. Small non-coding RNA profiling in breast cancer: plasma U6 snRNA, miR-451a and miR-548b-5p as novel diagnostic and prognostic biomarkers. Mol Biol Rep 2022;49:1955-71.
54. Satomi-Tsushita N, Shimomura A, Matsuzaki J, et al. Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer. PLoS One 2019;14:e0222024.
55. Wang J, Wang Q, Guan Y, et al. Breast cancer cell-derived microRNA-155 suppresses tumor progression via enhancing immune cell recruitment and antitumor function. J Clin Invest 2022;132:e157248.
56. Zhong W, Bao L, Yuan Y, Meng Y. CircRASSF2 acts as a prognostic factor and promotes breast cancer progression by modulating miR-1205/HOXA1 axis. Bioengineered 2021;12:3014-28.
57. Liang G, Ling Y, Mehrpour M, et al. Autophagy-associated circRNA circCDYL augments autophagy and promotes breast cancer progression. Mol Cancer 2020;19:65.
58. Garrido-Cano I, Pattanayak B, Adam-Artigues A, et al. MicroRNAs as a clue to overcome breast cancer treatment resistance. Cancer Metastasis Rev 2022;41:77-105.
59. Bao C, Chen J, Chen D, et al. MiR-93 suppresses tumorigenesis and enhances chemosensitivity of breast cancer via dual targeting E2F1 and CCND1. Cell Death Dis 2020;11:618.
60. Cataldo A, Cheung DG, Balsari A, et al. miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. Oncotarget 2016;7:786-97.
61. Papaspyropoulos A, Hazapis O, Lagopati N, et al. The role of circular RNAs in DNA damage response and repair. Cancers 2021;13:5352.
62. Lu X, Liu R, Wang M, et al. MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer. Oncogene 2020;39:234-47.
63. Lin S, Yu L, Song X, et al. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response. Cell Death Dis 2019;10:666.
64. Strasser A, Vaux DL. Cell death in the origin and treatment of cancer. Mol Cell 2020;78:1045-54.
65. Tao L, Wu YQ, Zhang SP. MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4. Neoplasma 2019;66:746-55.
66. Duan WJ, Bi PD, Ma Y, Liu NQ, Zhen X. MiR-512-3p regulates malignant tumor behavior and multi-drug resistance in breast cancer cells via targeting Livin. Neoplasma 2020;67:102-10.
67. Hao J, Du X, Lv F, Shi Q. Knockdown of circ_0006528 suppresses cell proliferation, migration, invasion, and adriamycin chemoresistance via regulating the miR-1236-3p/CHD4 axis in breast cancer. J Surg Res 2021;260:104-15.
68. Yang W, Gong P, Yang Y, Yang C, Yang B, Ren L. Circ-ABCB10 contributes to paclitaxel resistance in breast cancer through let-7a-5p/DUSP7 axis. Cancer Manag Res 2020;12:2327-37.
69. Chen Z, Shi T, Zhang L, et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett 2016;370:153-64.
70. Chen Y, Li X, Shi L, et al. Combination of 7-O-geranylquercetin and microRNA-451 enhances antitumor effect of Adriamycin by reserving P-gp-mediated drug resistance in breast cancer. Aging 2022;14:7156-69.
71. Zhang Z, Zhou Q, Luo F, et al. Circular RNA circ-CHI3L1.2 modulates cisplatin resistance of osteosarcoma cells via the miR-340-5p/LPAATβ axis. Hum Cell 2021;34:1558-68.
72. Liang H, Lin Z, Lin H, Zhao L, Huang W. circRNA_103615 contributes to tumor progression and cisplatin resistance in NSCLC by regulating ABCB1. Exp Ther Med 2021;22:934.
73. Lee JW, Guan W, Han S, Hong DK, Kim LS, Kim H. MicroRNA-708-3p mediates metastasis and chemoresistance through inhibition of epithelial-to-mesenchymal transition in breast cancer. Cancer Sci 2018;109:1404-13.
74. Wang G, Dong Y, Liu H, et al. Loss of miR-873 contributes to gemcitabine resistance in triple-negative breast cancer via targeting ZEB1. Oncol Lett 2019;18:3837-44.
75. Liu YY, Zhang LY, Du WZ. Circular RNA circ-PVT1 contributes to paclitaxel resistance of gastric cancer cells through the regulation of ZEB1 expression by sponging miR-124-3p. Biosci Rep 2019;39:BSR20193045.
76. Jhaveri K, Marmé F. Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Cancer Treat Rev 2024;123:102670.
77. Nakagawa T, Hayashi K, Ogawa A, et al. Bone marrow carcinomatosis in a stage IV breast cancer patient treated by letrozole as first-line endocrine therapy. Case Rep Oncol 2022;15:436-41.
78. Boscolo Bielo L, Trapani D, Nicolò E, et al. The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer. Cancer Treat Rev 2024;128:102761.
79. He YJ, Wu JZ, Ji MH, et al. miR-342 is associated with estrogen receptor-α expression and response to tamoxifen in breast cancer. Exp Ther Med 2013;5:813-8.
80. Yi J, Wang L, Hu GS, et al. CircPVT1 promotes ER-positive breast tumorigenesis and drug resistance by targeting ESR1 and MAVS. EMBO J 2023;42:e112408.
81. Ward A, Shukla K, Balwierz A, et al. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J Pathol 2014;233:368-79.
82. Zheng L, Meng X, Li X, et al. miR-125a-3p inhibits ERα transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer. FASEB J 2018;32:588-600.
83. Chen J, Shi P, Zhang J, et al. CircRNA_0044556 diminishes the sensitivity of triple-negative breast cancer cells to adriamycin by sponging miR-145 and regulating NRAS. Mol Med Rep 2022;25:51.
84. Misir S, Yaman SO, Petrović N, Sumer C, Hepokur C, Aliyazicioglu Y. circRNAs in drug resistance of breast cancer. Oncol Res 2022;30:157-72.
85. Ye X, Bai W, Zhu H, et al. MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN. BMB Rep 2014;47:268-73.
86. Wang S, Wang Y, Li Q, Li X, Feng X. A novel circular RNA confers trastuzumab resistance in human epidermal growth factor receptor 2-positive breast cancer through regulating ferroptosis. Environ Toxicol 2022;37:1597-607.
